Department of Biomedical Laboratory Science, Korea Nazarene University, Cheonan.
J Gene Med. 2011 Jul;13(7-8):365-72. doi: 10.1002/jgm.1583.
Long-term expression of the delivered target gene is critical for successful gene therapy. Recently, hepatic control region I (HCR I) originating from the apolipoprotein (apo)C-I pseudogene was shown to be a critical element for long-term gene expression in the liver of mice. HCR II is another hepatic control region of apoC-I.
HCR I, HCR II and HCR I/II-containing plasmids encoding factor IX were prepared and hydrodynamically transferred into the liver of normal and hemophilia B mice. Factor IX expression, clotting activity and formation of antibodies against the expressed gene product were compared.
HCR I-, HCR II- and HCR I/II-containing plasmids all induced long-term gene expression in both normal and hemophilia B mice. Post-transfection factor IX expression in the hemophilia B mice remained above 500 ng/ml for 210 days. Antibodies against human factor IX were detected at a low level in the serum, although they had no effect on the levels and clotting activity of the expressed factor IX.
We have shown in mouse models that hydrodynamic transfection of pBS-HCRII-HP-FIXA and pBS-HCRI/II-HP-FIXA was able to induce and maintain the expression and clotting activity of human factor IX for a long period of time at a potentially therapeutic level. With an appropriate delivery system, this type of plasmid vector could be clinically useful for the hepatic expression of therapeutic genes including human factor IX.
目的基因的长期表达对于成功的基因治疗至关重要。最近,来源于载脂蛋白(apo)C-I 假基因的肝控制区 I(HCR I)被证明是小鼠肝脏中长期基因表达的关键元件。HCR II 是 apoC-I 的另一个肝控制区。
制备含有因子 IX 的 HCR I、HCR II 和 HCR I/II 质粒,并通过流体动力学方法转移到正常和血友病 B 小鼠的肝脏中。比较因子 IX 的表达、凝血活性和对表达基因产物的抗体形成。
含 HCR I、HCR II 和 HCR I/II 的质粒均能在正常和血友病 B 小鼠中诱导长期基因表达。血友病 B 小鼠转染后因子 IX 的表达在 210 天内仍保持在 500ng/ml 以上。尽管它们对表达的因子 IX 的水平和凝血活性没有影响,但在血清中检测到针对人因子 IX 的低水平抗体。
我们在小鼠模型中表明,pBS-HCRII-HP-FIXA 和 pBS-HCRI/II-HP-FIXA 的流体动力学转染能够诱导和维持人因子 IX 的表达和凝血活性很长一段时间,达到潜在的治疗水平。通过适当的传递系统,这种质粒载体可用于包括人因子 IX 在内的治疗基因在肝脏中的表达,具有临床应用价值。